Status:
UNKNOWN
Impact of Preoperative Serum Albumin Level on Postoperative Outcomes in Chinese HCC Patients Treated With Surgery
Lead Sponsor:
Shanghai Zhongshan Hospital
Collaborating Sponsors:
Takeda
Conditions:
Hepatocellular Carcinoma
Eligibility:
All Genders
18+ years
Brief Summary
This is an observational and retrospective cohort study to evaluate the impact of the preoperative serum albumin concentration on postoperative outcomes among hepatocellular carcinoma (HCC) patients w...
Detailed Description
The impact of hypoalbuminemia on postoperative outcomes has been the subject of several investigations which agreed that hypoalbuminemia is an important risk factor for mortality and morbidity after v...
Eligibility Criteria
Inclusion
- Patients who diagnosed with HCC confirmed by histology/cytology or clinically criteria regardless of gender.
- HCC Patients who had received the first hepatectomy or liver transplantation (LT).
- Age ≥18 years at the start date of the hepatectomy or LT.
- HCC patients who had the value of serum albumin within 7 days prior to the surgery.
- HCC patients who had exemption of informed consent.
Exclusion
- HCC Patients with extrahepatic metastasis or other malignant tumours.
Key Trial Info
Start Date :
August 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2025
Estimated Enrollment :
480 Patients enrolled
Trial Details
Trial ID
NCT05970159
Start Date
August 1 2023
End Date
March 1 2025
Last Update
August 3 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, China, 200032